New drug cocktail shows promise against tough breast cancer
NCT ID NCT07197697
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests a new combination of two drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for patients with a common type of breast cancer (HR+/HER2-). The goal is to see if this approach can eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. About 30 people who have not yet been treated will take part. If the treatment works well, it may lead to a larger study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.